WELCOME TO BIOVEN
The Bioven Group's main focus is on the treatment of cancer. Bioven has a dual strategy of developing its own IP as well as in-licensing compounds to be developed through late-stage clinical trials prior to out-licensing to major healthcare or specialty pharma companies.
Meet us at the American Society of Clinical Oncologists (ASCO) annual meeting 2013 in Chicago, Illinois, 31 May – 4 June 2013
To arrange a meeting, please contact email@example.com